Weekly FDA Roundup: Oral GLP-1 approved in 50 days, CGMP cluster, and steroid-spiked supplements
Eli Lilly's Foundayo became the first new molecular entity approved under the FDA's CNPV pilot — 50 days, 294 days ahead of its PDUFA date. Three CGMP warning letters landed the same day, and a supplement recall surfaced undeclared prescription steroids in weight-gain capsules. March 27 to April 3, 2026.
This Week's Signal
FDA delivered its fastest drug approval on record this week under a new expedited pathway. A supplement recall exposed undeclared prescription steroids being sold as weight-gain capsules. And three CGMP warning letters landed on the same day, hitting a contract testing lab, a Chinese API manufacturer, and a device maker simultaneously. Not a quiet week.
Top Stories
1. FDA approves first oral GLP-1 drug under accelerated CNPV pathway — in 50 days
Eli Lilly's orforglipron (Foundayo) received FDA approval on April 1, 2026, for chronic weight management in adults with obesity or overweight with at least one comorbid condition. It is a once-daily oral GLP-1 receptor agonist tablet (no injection).
The pathway matters more than the drug itself. Foundayo is the first new molecular entity approved under the Commissioner's National Priority Voucher (CNPV) pilot program, introduced in June 2025. The review took 50 days, compared to the standard 10–12 month PDUFA timeline. The original PDUFA date was January 20, 2027; the approval came 294 days early.
The FDA will hold a public meeting on June 4, 2026 to evaluate the CNPV program's criteria, selection process, and review procedures. Written comments are due June 29.
2. FDA requests input on digital health technologies in clinical trials
The agency published a Request for Information on March 31 seeking public comment on advancing digital health technologies (wearables, sensors, digital biomarkers, mobile apps) in clinical investigations for drugs and biological products. The goal is to modernize data collection and patient monitoring in trials while meeting regulatory standards.
Comment deadline: June 1, 2026.
Why it matters: If you are running or planning clinical trials, DHT integration affects your data strategy, protocol design, and submission package. This RFI is an early signal of forthcoming guidance. Companies that engage now can shape what FDA expects, rather than getting caught flat-footed when the guidance drops.
Source: Federal Register
3. Final guidance: patient preference information in device and biologic reviews
FDA's Center for Devices and Radiological Health (CDRH) and Center for Biologics Evaluation and Research (CBER) jointly published final guidance on incorporating voluntary patient preference information (PPI) into regulatory benefit-risk assessments. Published March 30.
The guidance covers how companies can collect and submit patient-reported data on perceived benefits and risks across a product's full life cycle, from development through post-market surveillance.
Why it matters: This is final guidance, not draft. Device and biologic sponsors now have a defined framework for submitting PPI. Incorporating this into your regulatory strategy is now an expected part of the benefit-risk submission package. CDRH has been pushing patient-centric data collection for years; this codifies it.
Source: FDA Guidance
Enforcement
CGMP warning letters: March 31 cluster
Three warning letters published on the same day, each targeting a different sector.
Microbiological Testing & Consulting, LLC (contract pharma testing lab) Cited for multiple CGMP violations under 21 CFR 211: failure to establish scientifically sound lab controls, inadequate growth media qualification for microbiological testing, failure of the QC unit to investigate out-of-specification results, and data integrity lapses. If your products run through a contract testing lab, this letter is a template for what FDA inspectors are looking for. QC oversight and OOS investigation deficiencies are the two most common findings in third-party lab audits. Warning Letter
Physitemp Instruments, LLC (medical devices) Cited under 21 CFR Parts 820, 803, 801, and 830. The firm's clinical electronic thermometers and probes are Class II devices being marketed without premarket clearance (510(k)). Additional violations include failure to validate sterilization and laser welding processes, inadequate finished device acceptance procedures, poor complaint handling, and non-compliance with Medical Device Reporting (MDR) and Unique Device Identification (UDI) requirements. A failure across the entire quality system, layered on top of a fundamental marketing authorization problem. Warning Letter
Henan Lvyuan Pharmaceutical Co. Ltd. (API manufacturer, China) Issued by the Center for Veterinary Medicine. Violations include water leaks into production and warehouse areas, master production records missing critical processing parameters, and inadequate separation of operations creating cross-contamination risk. The facility's APIs are deemed adulterated under FD&C Act Section 501(a)(2)(B). Foreign supplier facilities with infrastructure-level deficiencies like these are unlikely to remediate quickly. Anticipate import alert risk for firms using this supplier. Warning Letter
Recalls
Supplement recall: undeclared prescription drugs in weight-gain capsules
Aphreseller / Buy-herbal.com issued a voluntary nationwide recall on March 30 of all lots of Kian Pee Wan Capsules, marketed for weight gain and appetite stimulation. FDA analysis found the product contains two undeclared active drug ingredients:
- Dexamethasone, a corticosteroid that suppresses immune function, causes elevated blood glucose, risks adrenal suppression with prolonged use, and can trigger serious cardiovascular events
- Cyproheptadine, a prescription antihistamine that causes sedation, dizziness, urinary retention, and blurred vision
Neither ingredient can legally be present in a dietary supplement. These capsules are an unapproved drug under the FD&C Act.
Why it matters: This is a pattern FDA has documented repeatedly in supplements marketed to specific ethnic communities, often via online marketplaces. The risk to consumers is compounded by the fact that dexamethasone suppresses the adrenal gland. Abrupt discontinuation after prolonged use can trigger adrenal crisis. For supplement brands: if your products share distribution channels with imported traditional remedy products, your customers are being exposed to safety failures in adjacent categories. That affects category trust.
Food recall: Clostridium botulinum risk in peeled garlic
Tops Friendly Markets recalled all codes of Christopher Ranch and Garland Fresh Peeled Garlic on April 1 due to potential Clostridium botulinum contamination. The risk was identified during a routine store inspection. The products were not maintained at temperatures sufficient to control the hazard. Distribution covered New York, Pennsylvania, and Vermont.
Peeled garlic stored in oil at inadequate temperatures is a well-documented botulism vector. This is a temperature control failure at retail, not at the manufacturer.
Regulatory actions to watch
TB diagnostic device reclassification proposed FDA proposed reclassifying Mycobacterium Tuberculosis Cell-Mediated Immunity Tests and Immune Response ELISpot Tests under 21 CFR Part 866. If finalized, this changes the regulatory pathway for these diagnostics. Comment deadline: May 29, 2026. Federal Register
Color additive petition: remove carcinogenic solvents The International Association of Color Manufacturers petitioned FDA to remove methylene chloride, trichloroethylene, and ethylene dichloride from permitted solvents in color additive regulations (21 CFR Part 73). All three are recognized carcinogens. FDA has filed the petition and opened public comment. Comment deadline: June 1, 2026. Federal Register
CNPV pilot program public input As noted above, the agency is soliciting feedback on the Commissioner's National Priority Voucher program following the Foundayo approval. Comment deadline: June 29, 2026. Public meeting: June 4, 2026.
Upcoming deadlines
| Deadline | Action |
|---|---|
| May 1, 2026 | Rockfish market name change — FDA request for information |
| May 29, 2026 | TB device reclassification — proposed rule comments |
| June 1, 2026 | Color additive petition (carcinogenic solvents) — comments |
| June 1, 2026 | Digital Health Technologies in clinical trials — RFI comments |
| June 4, 2026 | CNPV pilot program public meeting |
| June 29, 2026 | CNPV pilot program — written comments due |
Also in the database this week
- PRV issued for YUVIWEL (navepegritide) — rare pediatric disease priority review voucher (April 1). The drug approval itself was covered in last week's roundup.
- PRV issued for KRESLADI (marnetegragene autotemcel) — same as above; PRV notice published April 2.
- buydeltas.com warning letter — selling unauthorized ZYN nicotine pouch products without marketing authorization (March 31).
- INAPSINE (droperidol) commercial withdrawal determination — FDA confirmed the reference listed drug's withdrawal was commercial, not safety-related, keeping the ANDA pathway open for generic droperidol (March 31).
- Tradipitant NDA hearing decision — FDA issued a formal notice of decision on a hearing request regarding the proposed refusal to approve tradipitant capsules (March 31).
Policy Canary monitors FDA in real time. This roundup covers items published March 27 – April 3, 2026. All items sourced from the Federal Register, FDA.gov press announcements, and the Policy Canary regulatory database.
Get this in your inbox every Friday.
Free FDA intelligence digest. No account required.
